Biokinetics and clearance of inhaled gold ultrasmall-in-nano architectures.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
16 Sep 2020
16 Sep 2020
Historique:
received:
24
06
2020
accepted:
22
07
2020
entrez:
22
9
2022
pubmed:
22
7
2020
medline:
22
7
2020
Statut:
epublish
Résumé
Among an organism's entry portals, the respiratory tract is one of the most promising routes for non-invasive administration of therapeutics for local and systemic delivery. On the other hand, it is the subtlest to protect from environmental pollution and microbial occurrences. Here, the biokinetics, distribution, and clearance trends of gold ultrasmall-in-nano architectures administered through a single intranasal application have been quantitatively evaluated. Apart from reaching the lung parenchyma, the (bio)degradable nano-architectures are able to translocate as well to secondary organs and be almost completely excreted within 10 days. These findings further support the clinical relevance of plasmonic nanomaterials for oncology and infectious disease treatment and management. Notably, this investigation also provides crucial information regarding the associated risks as a consequence of the pulmonary delivery of nanoparticles.
Identifiants
pubmed: 36132776
doi: 10.1039/d0na00521e
pii: d0na00521e
pmc: PMC9417912
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3815-3820Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Biomaterials. 2013 Jul;34(22):5439-52
pubmed: 23639527
Nanomedicine. 2015 Jul;11(5):1189-99
pubmed: 25659645
Nanomedicine. 2018 Aug;14(6):1787-1795
pubmed: 29778890
ACS Nano. 2017 Jan 24;11(1):12-18
pubmed: 28068099
Mol Pharm. 2015 Aug 3;12(8):2688-96
pubmed: 25915006
Part Fibre Toxicol. 2013 May 16;10:19
pubmed: 23680060
Cancers (Basel). 2020 Apr 25;12(5):
pubmed: 32344838
Chem Commun (Camb). 2015 Jun 21;51(49):9939-41
pubmed: 25998799
Eur Respir J. 2020 Mar 5;55(3):
pubmed: 31624114
ACS Nano. 2017 Jan 24;11(1):375-383
pubmed: 27973764
Adv Mater. 2018 May;30(19):e1704307
pubmed: 29389049
ACS Appl Bio Mater. 2019 Oct 21;2(10):4464-4470
pubmed: 35021406
Inhal Toxicol. 2004 Jun;16(6-7):437-45
pubmed: 15204759
Anat Rec (Hoboken). 2014 Nov;297(11):2080-92
pubmed: 25312366
J Control Release. 2018 Sep 28;286:145-153
pubmed: 30009893
Int J Toxicol. 2018 Jan/Feb;37(1):4-27
pubmed: 29264927
Int J Oncol. 2011 Jan;38(1):51-9
pubmed: 21109925
Mol Pharm. 2017 Dec 4;14(12):4741-4750
pubmed: 29068693
ACS Omega. 2018 Sep 30;3(9):11796-11801
pubmed: 30320273
Nat Biotechnol. 2010 Dec;28(12):1275-6
pubmed: 21139613
ACS Nano. 2017 May 23;11(5):4542-4552
pubmed: 28443337
Environ Health Perspect. 2006 Aug;114(8):1172-8
pubmed: 16882521
Adv Mater. 2017 Oct;29(37):
pubmed: 28752600
Nanotoxicology. 2018 Oct;12(8):914-922
pubmed: 30132360